What's mbio prediction

**Mustang Bio (MBIO) stock is poised for significant growth**, as indicated by the analyst consensus and recent stock performance. Here's the analysis to support this prediction:

1. **Analyst Consensus and Price Target**: The analysts have a strong buy consensus rating for MBIO, with a price target of $2.00. This suggests that the current stock price of $0.31 has substantial upside potential.

|Ticker|Name|Current Price Target|Consensus Rating|Date|code|market_code|
|---|---|---|---|---|---|---|
|MBIO.O|Mustang Bio|2||20240513-20240613|MBIO|186|
|MBIO.O|Mustang Bio||Strong Buy|20240614|MBIO|186|

2. **Stock Performance and Market Sentiment**: The stock has seen a dramatic increase, with a 58% surge on a recent trading day, indicating a positive market sentiment. This rally is partly due to a high trading volume, which is more than 13.9 million shares, significantly higher than the average daily volume.
3. **Delisting Notice and Price Recovery Efforts**: Mustang Bio has received a delisting notice from Nasdaq due to trading below the required $1 minimum bid price. The company has until November 12, 2024, to regain compliance. The threat of delisting has spurred efforts to increase the stock price, which could contribute to a positive outcome.
4. **Earnings Estimates**: Despite a recent reduction in Q2 2024 earnings estimates by HC Wainwright, the company has beaten earnings per share estimates in the past, which could indicate a strong financial performance. Additionally, the FY2024 earnings estimate remains negative but less severe than previously anticipated.
5. **Stock Volatility and Investment Potential**: The stock has experienced significant volatility, with a wide range between its high and low prices. This volatility presents a high-risk, high-reward investment opportunity, especially if the company successfully addresses the delisting issue.
6. **Analyst Price Forecasts**: The 3 analysts with 12-month price forecasts have an average target of $12, with a high estimate of $18, suggesting a potential increase of over 3,700% from the current price. This indicates a strong belief in the stock's future performance.

In conclusion, the combination of the strong buy consensus, the potential for price recovery, the company's ability to beat earnings estimates, and the significant upside potential from analyst price targets all point to a positive outlook for Mustang Bio. However, investors should be aware of the associated risks, including the delisting threat and the company's current financial performance.